A first-in-class antisense oligonucleotide — RES-010 (Resalis Therapeutics, Turin, Italy) — may complement and enhance the efficacy of antiobesity drugs such as GLP-1 receptor agonists (RAs), ...

Details of a new drug that aims to treat the underlying causes of obesity are being presented at the annual meeting of the European Association for the Study of Diabetes (EASD) in Vienna, Austria ...

As Missloa2019 continues to grow, the goal is to expand its reach to more Cantonese-speaking women worldwide. With an impressive success rate of 70%, Missloa2019 aims to increase its visibility and ...

Have you ever wondered why some people seem to effortlessly manifest their desires while others struggle against unseen barriers? The answer lies not in sheer willpower but in the profound, often ...